ERBB2 and breast cancer: A TLR7 agonist has been shown to be synergistic with other treatment modalities in a mouse model of breast cancer.74 The combination of pembrolizumab and intratumoral SD-101 is being investigated in the I-SPY2 neoadjuvant clinical trial for women with early stage HER2-negative breast cancer (NCT01042379).